# OnCo record nct05076682 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05076682/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05076682", "NCT05076682" ;
  schema:name "Reverse Triple Negative Immune Resistant Breast Cancer"@en ;
  schema:description "A phase 2 trial of Trastuzumab rezetecan, SHR-A2102, Adebrelimab and Mecapegfilgrastim in Triple-negative breast cancer, run by Fudan University, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05076682/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05076682> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-rezetecan/>, <https://onco.cc/drugs/shr-a2102/>, <https://onco.cc/drugs/adebrelimab/>, <https://onco.cc/drugs/mecapegfilgrastim/> .